Addressing Evidence Gaps in Coronary Revascularization Trials

Gregg W. Stone*, Clyde W. Yancy, Mario Gaudino

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
JournalJAMA cardiology
DOIs
StateAccepted/In press - 2024

Funding

Conflict of Interest Disclosures: Dr Stone reported grants from the Patient-Centered Outcomes Research Institute paid to Mount Sinai Hospital through Cornell; personal fees from Pulnovo, Medtronic, Amgen, Boehringer Ingelheim, Abiomed, CorFlow, Cardiomech, Robocath, Daiichi Sankyo, Ablative Solutions, Vectorious, Miracor, Apollo Therapeutics, Elucid Bio, Abbott, Cardiac Success, Occlutech, Valfix, Zoll, HeartFlow, Shockwave, Impulse Dynamics, Adona Medical, Millennia Biopharma, Oxitope, HighLife, Elixir, Remote Cardiac Enablement, Aria, Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar, SpectraWave, Orchestra Biomed, Aria, Valfix, and Xenter; and grants from Shockwave, Biosense-Webster, Abbott, Abiomed, Bioventrix, Cardiovascular Systems, Phillips, Vascular Dynamics, Pulnovo, and V-wave. Dr Gaudino reported grants from the Patient-Centered Outcomes Research Institute, the National Institutes of Health, and the Canadian Institutes of Health Research. No other disclosures were reported.

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this